2. Search Result
Search Result
Results for "

Glioblastoma multiforme

" in MedChemExpress (MCE) Product Catalog:

64

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

2

Peptides

3

Inhibitory Antibodies

4

Natural
Products

1

Isotope-Labeled Compounds

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16900
    Rolipram
    Maximum Cited Publications
    19 Publications Verification

    (R,S)-Rolipram; (±)-Rolipram; ZK 62711

    		 Bacterial HIV Phosphodiesterase (PDE) Epigenetic Reader Domain Amyloid-β Infection Neurological Disease Cancer
    Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .
    Rolipram
  • HY-17595
    Mebendazole
    5+ Cited Publications

    		 Parasite Apoptosis Microtubule/Tubulin Infection Cancer
    Mebendazole is a highly effective, broad-spectrum antihelmintic against nematode infestations. Mebendazole also exhibits inhibitory effect against glioblastoma multiforme (GBM), inhibits Hedgehog pathway and tubulin polymerization. Mebendazole is orally active and can cross CNS penetration .
    Mebendazole
  • HY-N0421
    Cinobufagin
    5+ Cited Publications

    Cinobufagine

    		 Apoptosis Neurological Disease Cancer
    Cinobufagin is an anticancer agent that can be secreted by the Asiatic toad Bufo gargarizans. Cinobufagin induces the cell cycle arrests in the G1 phase or G2/M phase, leading to apoptosis in cancer cells. Cinobufagin inhibits tumor growth in melanoma and glioblastoma multiforme xenograft mouse models .
    Cinobufagin
  • HY-12456
    Duocarmycin SA

    		Antibiotic ADC Payload DNA Alkylator/Crosslinker Necroptosis Apoptosis Cancer
    Duocarmycin SA is an orally active antitumor antibiotic with an IC50 of 10 pM . Duocarmycin SA is an extremely potent cytotoxic agent capable of inducing a sequence-selective alkylation of duplex DNA. Duocarmycin SA demonstrates synergistic cytotoxicity against glioblastoma multiforme (GBM) cells treated with proton radiation in vitro .
    Duocarmycin SA
  • HY-P99948
    Etevritamab

    AMG-596

    		 EGFR CD3 Neurological Disease Cancer
    Etevritamab (AMG-596) is a bispecific T-cell engager that targets EGFRvIII and CD3. Etevritamab simultaneously binds CD3 on T cells and EGFRvIII on glioblastoma multiforme cells, thereby forming a bridge structure. Etevritamab triggers T-cell activation, proliferation, secretion of cytotoxic substances, and tumor cell lysis. Etevritamab extends overall survival and induces tumor regression in mouse models of glioblastoma multiforme. Etevritamab can be used for research related to glioblastoma .
    Etevritamab
  • HY-107643
    Reversan

    CBLC4H10

    		 P-glycoprotein Cancer
    Reversan (CBLC4H10) inhibits drug efflux mediated by P-glycoprotein (Pgp) and multidrug resistance protein 1 (MRP1), and exhibits oral activity. Reversan shows activity against glioblastoma multiforme and neuroblastoma models .
    Reversan
  • HY-13610A
    N1,N11-Diethylnorspermine tetrahydrochloride
    4 Publications Verification

    Diethylnorspermine tetrahydrochloride; DENSPM tetrahydrochloride; BENSPM tetrahydrochloride

    		 Caspase mTOR Cancer
    N1, N11-Diethylnorspermine tetrahydrochloride (DENSPM tetrahydrochloride) is a potent anticancer agent. N1,N11-Diethylnorspermine tetrahydrochloride activates polyamine catabolism and downregulates mTOR protein. N1,N11-Diethylnorspermine tetrahydrochloride induces the release of cytochrome c from mitochondria, resulting in activation of caspase 3. N1,N11-Diethylnorspermine tetrahydrochloride kills glioblastoma multiforme (GBM) through induction of SSAT (spermidine/spermine N1-acetyltransferase) coupled with H2O2 production .
    N1,N11-Diethylnorspermine tetrahydrochloride
  • HY-10996A
    KHS101 hydrochloride
    1 Publications Verification

    		 FGFR Neurological Disease Cancer
    KHS101 hydrochloride is a selective neuronal differentiation inducer that can cross the blood-brain barrier. KHS101 hydrochloride exhibits selective cytotoxicity against glioblastoma multiforme (GBM). KHS101 hydrochloride interacts with transforming acidic coiled-coil protein (TACC3). KHS101 hydrochloride can be used in GBM research .
    KHS101 hydrochloride
  • HY-14942A
    Berubicin hydrochloride

    RTA 744; WP 744; WP 769 hydrochloride

    		 NF-κB Apoptosis Caspase Drug Derivative Neurological Disease Cancer
    Berubicin (RTA 744) hydrochloride is a Doxorubicin (HY-15142A) analog that can cross the blood-brain barrier. Berubicin hydrochloride inhibits P-gp and MRP1-mediated efflux and suppresses glioblastoma multiforme (GBM). Berubicin hydrochloride exerts toxic effects on leukemia cells by activating nuclear factor κB (NF-κB) and induces apoptosis in neuroblastoma cells. Berubicin hydrochloride can be used in the study of tumors related to the nervous system .
    Berubicin hydrochloride
  • HY-131943
    DS44960156

    		Methylenetetrahydrofolate Dehydrogenase (MTHFD) Neurological Disease Cancer
    DS44960156 is a selective MTHFD2 inhibitor with moderate to low blood-brain barrier penetration (IC50=1.6 μM, Ki=1.23 μM). DS44960156 specifically binds to the active site of MTHFD2, disrupts redox homeostasis and blocks serine-mediated one-carbon metabolism, thereby increasing the NAD +/NADH ratio and ROS levels. DS44960156 not only effectively inhibits the proliferation of glioma cells, but also enhances the sensitivity of cells to glutamine starvation-induced death. DS44960156 binds to plasma proteins, shows no mutagenicity, carcinogenicity or acute oral toxicity, and serves as a research agent for glioblastoma multiforme and other cancers .
    DS44960156
  • HY-P99445
    Asunercept

    APG101; CAN008

    		 TNF Receptor Inflammation/Immunology Cancer
    Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein (hIgG1) targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) .
    Asunercept
  • HY-115630
    cRIPGBM chloride

    		RIP kinase Caspase Apoptosis Cancer
    cRIPGBM chloride, an orally active, proapoptotic derivative. cRIPGBM can be generated from glioblastoma multiforme (GBM) cancer stem cells (CSCs). cRIPGBM(chloride) targets to receptor-interacting protein kinase 2 (RIPK2) to induce caspase 1-dependent apoptosis. cRIPGBM(chloride) suppresses the formation of RIPK2/TAK1 (prosurvival complex), and increases the formation of RIPK2/caspase 1 (proapoptotic complex). cRIPGBM(chloride) exerts potent anti-tumor activity in vivo in animal models .
    cRIPGBM chloride
  • HY-167851
    CCX662

    		CXCR Neurological Disease Cancer
    CCX662 is a selective CXCR7 inhibitor with human IC50 values of 9 nM (buffer) and 18 nM (100% human serum), and rat IC50 of 14 nM (100% rat serum). CCX662 blocks CXCL12 binding to CXCR7, inhibits CXCR4-directed trans-endothelial migration of CXCR4 +/CXCR7 + cells. CCX662 can be used for the research of glioblastoma multiforme .
    CCX662
  • HY-167832
    PT109

    		JNK SGK ROCK Tau Protein MMP DNA/RNA Synthesis Pyruvate Kinase NF-κB COX NO Synthase Reactive Oxygen Species (ROS) Neurological Disease Cancer
    PT109 is an orally active, blood-brain barrier permeable multi-kinase inhibitor. By inhibiting PTBP1, PT109 promotes the switch of pyruvate kinase isoform from PKM2 to PKM1, thereby effectively inhibiting the proliferation and migration of glioblastoma multiforme and inducing its reprogramming into oligodendrocytes. PT109 also targets and regulates key signaling molecules such as JNK, SGK1, GSK3β to exert neuroprotective effects including promoting neurogenesis, inducing synapse formation and alleviating neuroinflammation. In Alzheimer's disease models, PT109 exhibits significant efficacy in improving spatial learning ability, along with excellent in vivo pharmacokinetic properties. PT109 can be used to investigate metabolic reprogramming of glioblastoma multiforme and neuroprotective mechanisms of Alzheimer's disease .
    PT109
  • HY-124813
    PDZ1i

    113B7

    		 FAK EGFR MMP NF-κB SDCBP Cancer
    PDZ1i (113B7) is a inhibitor of MDA-9/Syntenin, with selective binding to the PDZ1 domain. PDZ1i inhibits radiation-induced invasion of glioblastoma (GBM) cells, radiosensitizes GBM cells, and impairs GBM-related signaling pathways (including Src/EphA2, EGFRvIII/FAK, and NF-κB). PDZ1i reduces radiation-induced secretion of invasion-related proteases (MMP-2, MMP-9, ADAM9). PDZ1i shows anti-tumor effects in nude mice bearing intracranial U1242-luc xenografts or GBM xenografts. PDZ1i can be used for the study of glioblastoma (GBM), breast cancer and prostate cancer .
    PDZ1i
  • HY-159768A
    DOTAGA.Glu.(FAPi)2

    		Radionuclide-Drug Conjugates (RDCs) FAP Neurological Disease Cancer
    DOTAGA.Glu.(FAPi) 2 is a FAPI homodimer in which a central glutamic acid (Glu) linker connects FAPI and a chelator. Radiolabeled with gallium- 68, lutetium- 177 or terbium- 161, DOTAGA.Glu.(FAPi) 2 is applicable to FAP-positive cancer PET imaging studies. DOTAGA.Glu.(FAPi) 2 is suitable for research related to prostate adenocarcinoma and recurrent glioblastoma multiforme .
    DOTAGA.Glu.(FAPi)2
  • HY-142682
    SCP1-IN-1

    		Phosphatase Neurological Disease Cancer
    SCP1-IN-1 is a Small CTD Phosphatase 1 (SCP1) inhibitor with a human IC50 of 10 μM. SCP1-IN-1 inactivates SCP1, promotes REST transcription factor degradation, and reduces REST transcriptional activity. SCP1-IN-1 can be used for the research of glioblastoma multiforme .
    SCP1-IN-1
  • HY-112293
    GW2974

    		EGFR Cancer
    GW2974 is a potent dual inhibitor of EGFR and HER2 with IC50 value of 0.007 μM and 0.016 μM, respectively. GW2974 demonstrates in vitro inhibition of the EGFR and HER2 and inhibits the growth of tumor cell. GW2974 can be used for glioblastoma multiforme (GBM) disease research .
    GW2974
  • HY-156679
    VK-0214

    		Thyroid Hormone Receptor Neurological Disease Cancer
    VK-0214 is an agonist of the thyroid β receptor (TRβ). By activating the expression of ABCD2, it can reduce the accumulation of very long-chain fatty acids (VLCFAs) and further alleviate glioblastoma multiforme. VK-0214 has the effect of regulating fatty acid metabolism and can be used in the research of X-linked adrenoleukodystrophy (X-ALD) .
    VK-0214
  • HY-156019
    FGFR1 inhibitor-10

    		FGFR Cancer
    FGFR1 inhibitor-10 (Compound 4i) is an FGFR1 inhibitor (IC50: 28 nM). FGFR1 inhibitor-10 inhibits the phosphorylation of FGFR1. FGFR1 inhibitor-10 has anti-angiogenic, anti-invasion activity, and anti-tumor effect .
    FGFR1 inhibitor-10
  • HY-19345A
    Vacquinol-1 dihydrochloride

    NSC13316 dihydrochloride

    		 p38 MAPK Neurological Disease Cancer
    Vacquinol-1 (NSC13316) dihydrochloride is a MKK4-specific activator that activates the MAPK pathway. Vacquinol-1 dihydrochloride inhibits the growth, migration and colony formation, and induces apoptosis of cancer cells. Vacquinol-1 dihydrochloride is applicable to research related to cancers such as hepatocellular carcinoma .
    Vacquinol-1 dihydrochloride
  • HY-149145
    Ena15

    		Anaplastic lymphoma kinase (ALK) Fat Mass and Obesity-associated Protein (FTO) Cancer
    Ena15 is an ALKBH5 inhibitor. Ena15 enhances the demethylase activity of FTO. Ena15 increases m 6A RNA level, and stabilizes FOXM1 mRNA. Ena15 suppresses the growth activity of glioblastoma multiforme .
    Ena15
  • HY-17595R
    Mebendazole (Standard)

    		Reference Standards Parasite Apoptosis Microtubule/Tubulin Infection Cancer
    Mebendazole (Standard) is the analytical standard of Mebendazole. This product is intended for research and analytical applications. Mebendazole is a highly effective, broad-spectrum antihelmintic against nematode infestations. Mebendazole also exhibits inhibitory effect against glioblastoma multiforme (GBM), inhibits Hedgehog pathway and tubulin polymerization. Mebendazole is orally active and can cross CNS penetration .
    Mebendazole (Standard)
  • HY-122910
    RIPGBM

    		Apoptosis Cancer
    RIPGBM is a selective inducer of apoptosis in glioblastoma multiforme (GBM) cancer stem cells (CSCs) with an EC50 of ≤500 nM .
    RIPGBM
  • HY-W012166
    N-Succinimidyl bromoacetate

    NHS-Bromoacetate

    		 Biochemical Assay Reagents Infection
    N-Succinimidyl bromoacetate (NHS-Bromoacetate) is a heterobifunctional crosslinking reagent, mainly used to modify the ɛ-amino group of lysine side chains. By covalently linking its bromoacetyl moiety to the ɛ-amino group of lysine in peptidomimetics, N-Succinimidyl bromoacetate enables their conjugation with thiol-modified nanoparticles via thioether bonds. N-Succinimidyl bromoacetate also performs bromoacetylation modification on carrier proteins, which then forms stable thioether bonds with the thiol groups of cysteine in peptides, thus efficiently preparing soluble peptide-protein conjugates with high substitution ratios. N-Succinimidyl bromoacetate can be used to prepare activated Sepharose derivatives for affinity chromatography, protein affinity labeling reagents, and peptide-protein immunogen conjugates with non-immunogenic linkages. N-Succinimidyl bromoacetate is applicable to studies related to HIV-1 infection and glioblastoma multiforme .
    N-Succinimidyl bromoacetate
  • HY-14942
    Berubicin

    RTA 744 free base; WP 744 free base; WP 769

    		 NF-κB Apoptosis Caspase Drug Derivative Neurological Disease Cancer
    Berubicin (RTA 744 free base) is a Doxorubicin (HY-15142A) analog that can cross the blood-brain barrier. Berubicin inhibits P-gp and MRP1-mediated efflux and suppresses glioblastoma multiforme (GBM). Berubicin exerts toxic effects on leukemia cells by activating nuclear factor κB (NF-κB) and induces apoptosis in neuroblastoma cells. Berubicin can be used in the study of tumors related to the nervous system .
    Berubicin
  • HY-148833
    MDM2-p53-IN-16

    		MDM-2/p53 Cancer
    MDM2-p53-IN-16 is a MDM2-p53 complex inhibitor with an IC50 value of 4.3 nM to dissociate human p53/MDM2 complex. MDM2-p53-IN-16 reactivates p53, and induces Glioblastoma Multiforme (GBM) cell apoptosis and cell-cycle arrest. MDM2-p53-IN-16 can be used for the cancer research .
    MDM2-p53-IN-16
  • HY-N3001
    Isolinderalactone
    1 Publications Verification

    		 STAT VEGFR Bcl-2 Family Survivin IAP NF-κB Apoptosis Caspase Neurological Disease Inflammation/Immunology Cancer
    Isolinderalactone is a sesquiterpene that exhibits anti-cancer, anti-inflammatory, and neuroprotective effects. Isolinderalactone inhibits VEGF expression and tyrosine phosphorylation of VEGFR2. Isolinderalactone decreases viability and induces apoptosis in U-87 glioblastoma (GBM) cells and colorectal cancer (CRC) cells. Isolinderalactone induces G2/M phase cell cycle arrest, ROS generation, pJNK/p38 MAPK activation, in colorectal cancer (CRC) cells. Isolinderalactone blocks LPS (HY-D1056)-induced NF-κB activation while activating Nrf2-HMOX1 signaling in RAW264.7 macrophages. Isolinderalactone improves cognitive dysfunction in APP/PS1 mice. Isolinderalactone can be used for the study of Glioblastoma multiforme (GBM), colorectal cancer, Alzheimer’s disease and acute lung injury .
    Isolinderalactone
  • HY-N1989
    Bacoside A

    		Na+/K+ ATPase CaMK Apoptosis Cholinesterase (ChE) NO Synthase NF-κB Neurological Disease Cancer
    Bacoside A is an orally active, blood-brain barrier-permeable triterpenoid saponin that modulates the activities of ATPases, AChE, CaMK2A and iNOS. Derived from Bacopa monniera. Bacoside A exerts significant antioxidant, anti-inflammatory and anti-apoptotic effects by maintaining ion balance, scavenging reactive oxygen species, stabilizing cell membranes, and regulating the expression of NF-κB and apoptosis-related proteins. Bacoside A counteracts morphine-induced reductions in Na +/K +-ATPase, Ca 2+-ATPase and Mg 2+-ATPase activities, increases mitochondrial membrane potential, and decreases intracellular reactive oxygen species levels. Bacoside A specifically binds to calcium/calmodulin-dependent protein kinase IIA to trigger endoplasmic reticulum calcium release. Bacoside A exhibits non-apoptotic cytotoxicity against glioblastoma cells while protecting normal nerve cells from stress-induced damage. Bacoside A is applicable to the research of Parkinson's disease and glioblastoma multiforme .
    Bacoside A
  • HY-125964
    LLP-3

    		Survivin Cancer
    LLP-3 is a potent Survivin inhibitor that disrupts the Survivin-Ran interaction in cancer cells. LLP-3 can be used in the research of Glioblastoma multiforme (GBM) .
    LLP-3
  • HY-12455
    Duocarmycin A

    		ADC Payload Antibiotic DNA Alkylator/Crosslinker Apoptosis Caspase Cancer
    Duocarmycin A is an antitumor antibiotic and DNA alkylating agent with broad-spectrum antibacterial activity, which can serve as a payload for synthesizing antibody-drug conjugates (ADCs). Duocarmycin A selectively binds to the AT-rich minor groove of DNA, forms covalent adducts by alkylating the adenine N3 residue, thereby disrupting DNA structure and inhibiting its replication and transcription. Duocarmycin A induces apoptosis, sub-G1 phase accumulation and chromatin condensation, reduces the levels of pro-caspase-3/9, and induces p53-independent p21 expression. Duocarmycin A is widely used in the research of various malignancies, including leukemia, sarcoma, glioblastoma, as well as multiple solid tumor models such as lung cancer, breast cancer, and colorectal cancer .
    Duocarmycin A
  • HY-P1828A
    EGFRvIII peptide (PEPvIII) TFA

    		EGFR Cancer
    EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy .
    EGFRvIII peptide (PEPvIII) TFA
  • HY-129356A
    (S)-Seco-Duocarmycin SA

    		Drug Isomer Cancer
    (S)-Seco-Duocarmycin SA is the S-enantiomer of Seco-Duocarmycin SA (HY-129356). Seco-Duocarmycin SA can be used for cancer research .
    (S)-Seco-Duocarmycin SA
  • HY-P1828
    EGFRvIII peptide (PEPvIII)

    		EGFR Cancer
    EGFRvIII peptide (PEPvIII) is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide represents a truly tumor-specific target for antitumor immunotherapy .
    EGFRvIII peptide (PEPvIII)
  • HY-175530
    OLIG2-IN-1

    		OLIG2 Cancer
    OLIG2-IN-1 is a potent and selective oligodendrocyte transcription factor 2 (OLIG2) inhibitor. OLIG2-IN-1 directly and dose-dependently downregulates nuclear OLIG2 levels with an IC50 value of 0.88 μM. OLIG2-IN-1 exhibits strong anti-proliferative activity in U87 and U251 cells with IC50 values of 7.02 μM and 6.43 μM, respectively. OLIG2-IN-1 can be used for the research of cancer, such as glioblastoma multiforme .
    OLIG2-IN-1
  • HY-163121
    PST3.1a

    		Glycosyltransferase TGF-β Receptor FAK Galectin Collagen Endocrinology Cancer
    PST3.1a is an orally active and brain-penetrant N-acetylglucosamine glycosyltransferase (MGAT5) inhibitor with a human IC50 of 2 µM. PST3.1a inhibits TGFβR and FAK signaling pathway activity. PST3.1a alters β1,6-GlcNAc N-glycans and microtubule/microfilament integrity, increases OLIG2 expression, and inhibits proliferation, migration, invasiveness, and clonogenic capacities of glioblastoma initiating cells. PST3.1a reduces invasive and proliferative capacity of glioblastoma initiating cells in orthotopic graft models, increases overall survival of orthotopic graft model mice. PST3.1a blunts MGAT5 overexpression, decreases renal fibrosis via collagen 1, collagen 4, and galectin 3 downregulation in a rat chronic kidney disease model. PST3.1a can be used for the research of glioblastoma multiforme and chronic kidney disease .
    PST3.1a
  • HY-13610B
    N1,N11-Diethylnorspermine hydrobromide

    		Caspase Cancer
    N1,N11-Diethylnorspermine hydrobromide is a potent anticancer agent. N1,N11-Diethylnorspermine hydrobromide is a spermine analog that activates polyamine catabolism. N1,N11-Diethylnorspermine hydrobromide induces the release of cytochrome c from mitochondria, resulting in activation of caspase 3. N1,N11-Diethylnorspermine hydrobromide kills glioblastoma multiforme (GBM) cells through induction of SSAT (spermidine/spermine N1-acetyltransferase) coupled with H2O2 production .
    N1,N11-Diethylnorspermine hydrobromide
  • HY-13610
    N1,N11-Diethylnorspermine

    Diethylnorspermine; BENSPM; DENSPM; BE-333

    		 Caspase mTOR Cancer
    N1,N11-Diethylnorspermine is a synthetic analog of the naturally occurring polyamine spermine, can induce polyamine depletion and inhibit tumor cell growth. N1,N11-Diethylnorspermine activates polyamine catabolism and downregulates mTOR protein. N1,N11-Diethylnorspermine induces the release of cytochrome c from mitochondria, resulting in activation of caspase 3. N1,N11-Diethylnorspermine tetrahydrochloride kills glioblastoma multiforme (GBM) through induction of SSAT (spermidine/spermine N1-acetyltransferase) coupled with H2O2 production .
    N1,N11-Diethylnorspermine
  • HY-164401
    QBS10072S

    		DNA Alkylator/Crosslinker Apoptosis Cancer
    QBS10072S is a LAT1-selective substrate with blood-brain barrier permeability that inhibits tumor growth. QBS10072S enters LAT1-expressing tumor cells via LAT1-mediated active transport, induces interstrand DNA cross-linking and cell apoptosis, and reduces leptomeningeal dissemination. QBS10072S can be used in studies related to glioblastoma multiforme, diffuse intrinsic pontine glioma, triple-negative breast cancer brain metastases, and aggressive T-cell lymphoma .
    QBS10072S
  • HY-150791
    FLDP-5

    		Reactive Oxygen Species (ROS) DNA/RNA Synthesis Cancer
    FLDP-5 is a blood-brain barrier (BBB) penetrant curcuminoid analogues. FLDP-5 can induce production of ROS (Reactive Oxygen Species), DNA damage and cell cycle S phase arrest. FLDP-5 exhibits highly potent tumour-suppressive effects with anti-proliferative and anti-migratory activities on LN-18 cells .
    FLDP-5
  • HY-16900R
    Rolipram (Standard)

    (R,S)-Rolipram (Standard); (±)-Rolipram (Standard); ZK 62711 (Standard)

    		 Reference Standards Bacterial HIV Phosphodiesterase (PDE) Epigenetic Reader Domain Amyloid-β Neurological Disease Cancer
    Rolipram (Standard) is the analytical standard of Rolipram (HY-16900). This product is intended for research and analytical applications. Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .
    Rolipram (Standard)
  • HY-N0421R
    Cinobufagin (Standard)

    Cinobufagine (Standard)

    		 Reference Standards Apoptosis Neurological Disease Cancer
    Cinobufagin (Standard) is the analytical standard of Cinobufagin. This product is intended for research and analytical applications. Cinobufagin is an anticancer agent that can be secreted by the Asiatic toad Bufo gargarizans. Cinobufagin induces the cell cycle arrests in the G1 phase or G2/M phase, leading to apoptosis in cancer cells. Cinobufagin inhibits tumor growth in melanoma and glioblastoma multiforme xenograft mouse models .
    Cinobufagin (Standard)
  • HY-13610AR
    N1,N11-Diethylnorspermine tetrahydrochloride (Standard)

    Diethylnorspermine tetrahydrochloride (Standard); DENSPM tetrahydrochloride (Standard); BENSPM tetrahydrochloride (Standard)

    		 Caspase mTOR Reference Standards Cancer
    N1,N11-Diethylnorspermine (tetrahydrochloride) (Standard) is the analytical standard of N1,N11-Diethylnorspermine (tetrahydrochloride). This product is intended for research and analytical applications. N1, N11-Diethylnorspermine tetrahydrochloride (DENSPM tetrahydrochloride) is a potent anticancer agent. N1,N11-Diethylnorspermine tetrahydrochloride activates polyamine catabolism and downregulates mTOR protein. N1,N11-Diethylnorspermine tetrahydrochloride induces the release of cytochrome c from mitochondria, resulting in activation of caspase 3. N1,N11-Diethylnorspermine tetrahydrochloride kills glioblastoma multiforme (GBM) through induction of SSAT (spermidine/spermine N1-acetyltransferase) coupled with H2O2 production .
    N1,N11-Diethylnorspermine tetrahydrochloride (Standard)
  • HY-174338
    GPER/Bcl-2-IN-1

    		Estrogen Receptor/ERR Bcl-2 Family Neurological Disease Cancer
    GPER/Bcl-2-IN-1 is a GPER/Bcl-2 inhibitor. GPER/Bcl-2-IN-1 can inhibit the proliferation and neurospheres formation of glioblastoma cells. GPER/Bcl-2-IN-1 can be used for the study of glioblastoma multiforme (GBM) .
    GPER/Bcl-2-IN-1
  • HY-162510
    SPDZi1

    		NF-κB Cancer
    SPDZi1 is a potent and selective syntenin inhibitor that binds to PDZ1 and PDZ2 domains of syntenin. SPDZi1 binds to the syntenin PDZ tandem (STNPDZ) with a Kd of 3.6 μM. SPDZi1 suppresses glioblastoma and reduces the activation of NF-κB, a downstream effector of syntenin .
    SPDZi1
  • HY-149374
    Tubulin inhibitor 36

    		Microtubule/Tubulin Cancer
    Tubulin inhibitor 36 (Compound 10) is a novel and potent tubulin inhibitor and inhibits the polymerization of microtubular protein then induces apoptosis with an IC50 value of 1.5±0.1 μM. Tubulin inhibitor 36 (Compound 10) has significant anti-mitotic effect and exhibits activities against glioblastoma cells. Tubulin inhibitor 36 (Compound 10) has anti-tumor effects and can be used for glioblastoma multiforme (GBM) research .
    Tubulin inhibitor 36
  • HY-163290
    HDAC-MB

    		Fluorescent Dye Monoamine Oxidase Cancer
    HDAC-MB a probe that is activated by HDAC6 and can detect and eliminate glioma cells through activation by HDAC6. HDAC-MB reveals antimetastatic and antiproliferative properties, inhibits glioma invasion and induces cellular apoptosis .
    HDAC-MB
  • HY-W747797
    Cinobufagine-d3

    		Isotope-Labeled Compounds Apoptosis Cancer
    Cinobufagine-d3 is the deuterium labeled Cinobufagin (HY-N0421). Cinobufagin is an anticancer agent that can be secreted by the Asiatic toad Bufo gargarizans. Cinobufagin induces the cell cycle arrests in the G1 phase or G2/M phase, leading to apoptosis in cancer cells. Cinobufagin inhibits tumor growth in melanoma and glioblastoma multiforme xenograft mouse models .
    Cinobufagine-d3
  • HY-155458
    HYDAMTIQ

    		PARP Inflammation/Immunology Cancer
    HYDAMTIQ is a PARP-1/2 inhibitor (IC50: 29-38 nM) with anticancer, anti-inflammatory, and ischemic protective effects. HYDAMTIQ inhibits pulmonary PARP activity, is effective against allergen-induced cough and dyspnea, and inhibits bronchial hyperresponsiveness to methacholine. HYDAMTIQ has broad-spectrum tumor suppressor effects, including ovarian and breast cancers, prostate and pancreatic tumors, and glioblastoma multiforme. HYDAMTIQ has demonstrated in vivo efficacy in animal models of cerebral ischemia, asthma, cancer, and more .
    HYDAMTIQ
  • HY-150794
    FLDP-8

    		Others Cancer
    FLDP-8 is a curcuminoid analogues, has potent anti-cancer effects. FLDP-8 can induce cell death with an IC50 value of 4 μM in LN-18 cells .
    FLDP-8

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: